MIRABEGRON
| Brand name | MYRBETRIQ |
|---|---|
| Active ingredient | MIRABEGRON |
| Strength | 25MG |
| Dosage form | TABLET, EXTENDED RELEASE |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | June 2012 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10842780*PED | March 2030 | — |
| 12059409*PED | March 2030 | — |
| 11707451*PED | March 2030 | — |
| 12097189*PED | March 2030 | — |
| 12059409 | September 2029 | product |
| 10842780 | September 2029 | product |
| 12097189 | September 2029 | use U-3670 |
| 11707451 | September 2029 | use U-3670 |
| 8772315*PED | April 2029 | — |
| 8772315 | October 2028 | use U-2300 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.